Clinical Study of Lipoic Acid on Ischemic Heart Failure

Inclusion Criteria: * patients ≥ 18 years of age, male or female. * Patients with a diagnosis of AMI (\>30 days) according to the global definition. ③Patients with a diagnosis of CHF (NYHA class II-IV) and reduced ejection fraction (EF =\< 50%) and elevated BNP（NT-proBNP≥600pg/ml or BNP≥150pg/ml; NT-proBNP ≥400 pg/mL or BNP ≥100 pg/mL if patients was hospitalized for heart failure within 12months). * Patients must be treated with standardized heart failure medications treatment at a stable dose for at least 4 weeks. * Patients must give written informed consent before any assessment is performed. Exclusion Criteria: * Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer. * allergy to any of the study drugs, drugs of similar chemical classes（Vitamin B） as well as known or suspected contraindications to the study drugs. * Previous history of intolerance to recommended target doses of α-LA. * Current acute decompensated HF (exacerbation of chronic HF manifested by signs and symptoms that may require intravenous therapy). ⑤ Symptomatic hypotension and/or a SBP \< 100 mmHg. ⑥ Severe liver function abnormalities (ALT or AST more than 3 times of the normal upper limit). ⑦ Estimated GFR \< 30 mL/min/1.73m2 as measured by the simplified MDRD formula. ⑧ Serum potassium \> 5.2 mmol/L. ⑨ Pregnant women or women preparing for birth.